InvestorsHub Logo

$Pistol Pete$

04/04/22 9:10 PM

#867 RE: Polyphemus #866

Ran away from it

Bigspirit1

04/07/22 3:43 PM

#868 RE: Polyphemus #866

Agreed. Clearly it was a mistake to go after the migraine indication first. The question is can ECOR stay alive long enough to develop the other more lucrative indications. They have a good structure awaiting product.